Welcome from the Director of The Tisch Cancer Institute

We are leading the way in tackling myeloproliferative neoplasms. With continued grant funding since 2006, a consortium led by Mount Sinai investigators is working on novel approaches using drug combinations, including small molecule inhibitors, to dry up pools of malignant stem cells in the tumor microenvironment. Similarly, with long-term grant funding, we are leading cutting-edge clinical trials that could reshape therapeutic strategies for graft-versus-host disease, a serious complication of allogeneic stem cell transplantation.

We are investigating the role of the FGF2 gene in survival of disseminated breast cancer cells in the bone microenvironment. We are exploring DNA damage repair in prostate cancer to provide insight on developing novel combination treatments. And, we are studying glioblastoma margins to curb tumor invasion and relapse. These studies and more are supported by competitive grant funding.

Additionally, we’re excited that Dmitriy Zamarin, MD, PhD, joined our faculty in September 2023 as Head of the Section of Gynecologic Medical Oncology. With clinical and research expertise in immunotherapy and drug devepment for gynecologic cancers, Dr. Zamarin is impacting therapeutic options for patients.

Our talented faculty take on leadership roles at The Tisch Cancer Institute as well as international cancer organizations, helping to chart new research frontiers. They engage in a robust interdisciplinary exchange that fuels ideas for future directions in tackling cancer and ensures our continued progress.

Translating research findings into clinical applications is a hallmark of our program. Thanks to the dedication of our faculty and staff, support from donors and grantors, and trust in our patient care from physician colleagues throughout the country, The Mount Sinai Hospital is ranked No. 12 in the nation for cancer in 2023-2024 by the U.S. News & World Report®. We are grateful for the ongoing votes of confidence that help The Tisch Cancer Institute remain at the forefront.